On Wednesday, bluebird bio Inc (NASDAQ:BLUE)’s shares declined -2.83% to $165.71.
bluebird bio Inc (BLUE) declared that data from the ongoing Phase 1/2 HGB-205 study of LentiGlobin BB305 Drug Product will be presented in an oral presentation on June 13, 2015 at the 20th Congress of the European Hematology Association (EHA) in Vienna, Austria.
bluebird bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, declared that it has met with regulatory authorities in Europe and the United States to talk about potential approval pathways for its LentiGlobin BB305 product candidate for the treatment of beta-thalassemia major. These talk about have resulted in general agreement from both agencies regarding bluebird bio’s development plans, which could potentially result in accelerated approvals.
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, in addition to a phase I study in the United States for the treatment of severe SCD.
Approach Resources Inc. (NASDAQ:AREX)’s stated results for first quarter 2015. Highlights for first quarter 2015 comprise:
- Production was 14.3 MBoe/d, a 21% enhance over the preceding-year quarter
- EBITDAX was $33.4 million, or $0.83 per diluted share
- Per unit cash operating expenses reduced 27% from the preceding-year period
- Adjusted net loss was $1.3 million, or $0.03 per diluted share
- Average IP for horizontal Wolfcamp wells in first quarter 2015 was 723 Boe/d (56% oil)
- Lenders reaffirmed credit facility commitment amount of $450 million effective April 15
Approach Resources Inc., an independent energy company, focuses on the exploration, development, production, and acquisition of unconventional oil and gas reserves in the United States.
At the end of Wednesday’s trade, Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY)‘s shares dipped -2.23% to $0.700.
Oncolytics Biotech, Inc. (USA) (ONCY) declared that following submission to the U.S. Food and Drug Administration (“FDA”) for review, the Investigational New Drug Application containing the protocol titled “MC1472: Phase 1 Study of Replication Competent Reovirus (REOLYSIN®) in Combination with GM-CSF in Pediatric Patients with Relapsed or Refractory Brain Tumors” is now active. The study sponsor is Mayo Clinic based in Rochester, Minnesota, and the Study Chair is Dr. Richard Bram of Mayo Clinic.
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a cancer therapeutic that is in various clinical trials for human use.
Pain Therapeutics, Inc. (NASDAQ:PTIE), ended its Wednesday’s trading session with -2.76% loss, and closed at $2.11.
Pain Therapeutics, Inc. (PTIE) declared top-line results of an FDA Category 3 Human Abuse Potential Study with REMOXY Extended-Release Capsules CII, its lead drug candidate that is specifically designed to discourage certain common methods of drug tampering and misuse. This study demonstrated with statistical significance (p<0.0001) that both intact and chewed REMOXY were less “liked” than immediate-release oxycodone on the two primary endpoints, Drug Liking and Drug High. The Abuse Potential study was conducted in non-dependent, recreational opioid users, as recommended by FDA guidelines.
Pain Therapeutics, Inc., a biopharmaceutical company, develops novel drugs in the United States. The company’s lead drug candidate is REMOXY, an extended-release oral formulation of oxycodone for the administration of moderate-to-severe pain when a continuous and around-the-clock opioid analgesic is needed.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
